MELISSA MASSE: Open Payments
NPI 1851625271 · BRISTOL, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,257 in 55 payments from 14 companies in 2025. Trend: 2023 $1,110 · 2024 $1,171 · 2025 $1,257
Food & beverage: $1,257
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $335 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $213 |
| ABBVIE INC. | 19 | $170 |
| Corium, LLC | 9 | $148 |
| Alkermes, Inc. | 3 | $83 |
| Janssen Pharmaceuticals, Inc | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Lundbeck LLC | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
Products named: FANAPT, CAPLYTA, VRAYLAR, Azstarys, HETLIOZ, REXULTI, SPRAVATO, TRINTELLIX.
Industry payments across CT — which companies pay providers there.
